|
1
|
Hofstetter W, Swisher SG, Correa AM, Hess
K, Putnam JB Jr, Ajani JA, Dolormente M, Francisco R, Komaki RR,
Lara A, et al: Treatment outcomes of resected esophageal cancer.
Ann Surg. 236:376–384. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sjoquist KM, Burmeister BH, Smithers BM,
Zalcberg JR, Simes RJ, Barbour A and Gebski V; Australasian
Gastro-Intestinal Trials Group, : Survival after neoadjuvant
chemotherapy or chemoradiotherapy for resectable oesophageal
carcinoma: An updated meta-analysis. Lancet Oncol. 12:681–692.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Japanese Society for Esophageal Diseases,
. Japanese Classification of Esophageal Cancer. 10th. Kanehara
& Co., Ltd.; Tokyo, Japan: 2007
|
|
5
|
Ando N, Kato H, Igaki H, Shinoda M, Ozawa
S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lajer H and Daugaard G: Cisplatin and
hypomagnesemia. Cancer Treat Rev. 25:47–58. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lam M and Adelstein DJ: Hypomagnesemia and
renal magnesium wasting in patients treated with cisplatin. Am J
Kidney Dis. 8:164–169. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Evans TR, Harper CL, Beveridge IG,
Wastnage R and Mansi JL: A randomised study to determine whether
routine intravenous magnesium supplements are necessary in patients
receiving cisplatin chemotherapy with continuous infusion
5-fluorouracil. Eur J Cancer. 31A:1–178. 1995.
|
|
9
|
Bodnar L, Wcislo G, Gasowska-Bodnar A,
Synowiec A, Szarlej-Wcisło K and Szczylik C: Renal protection with
magnesium subcarbonate and magnesium sulphate in patients with
epithelial ovarian cancer after cisplatin and paclitaxel
chemotherapy: A randomised phase II study. Eur J Cancer.
44:2608–2614. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kidera Y, Kawakami H, Sakiyama T, Okamoto
K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara
K, et al: Risk factors for cisplatin-induced nephrotoxicity and
potential of magnesium supplementation for renal protection. PLoS
One. 9:e1019022014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Muraki K, Koyama R, Honma Y, Yagishita S,
Shukuya T, Ohashi R, Takahashi F, Kido K, Iwakami S, Sasaki S, et
al: Hydration with magnesium and mannitol without furosemide
prevents the nephrotoxicity induced by cisplatin and pemetrexed in
patients with advanced non-small cell lung cancer. J Thorac Dis.
4:562–568. 2012.PubMed/NCBI
|
|
12
|
Yoshida T, Niho S, Toda M, Goto K, Yoh K,
Umemura S, Matsumoto S, Ohmatsu H and Ohe Y: Protective effect of
magnesium preloading on cisplatin-induced nephrotoxicity: A
retrospective study. Jpn J Clin Oncol. 44:346–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rude RK: Magnesium metabolism and
deficiency. Endocrinol Metab Clin North Am. 22:377–395.
1993.PubMed/NCBI
|
|
14
|
Rabbani SA: Molecular mechanism of action
of parathyroid hormone related peptide in hypercalcemia of
malignancy: Therapeutic strategies (Review). Int J Oncol.
16:197–206. 2000.PubMed/NCBI
|
|
15
|
Sobin LH, Gospodarowicz MK and Wittekind
C: International Union Against Cancer: TNM Classification of
Malignant Tumours. 7th. Wiley-Blackwell; Hoboken, NJ: pp. 66–72.
2010
|
|
16
|
Hara H, Tahara M, Daiko H, Kato K, Igaki
H, Kadowaki S, Tanaka Y, Hamamoto Y, Matsushita H, Nagase M and
Hosoya Y: Phase II feasibility study of preoperative chemotherapy
with docetaxel, cisplatin, and fluorouracil for esophageal squamous
cell carcinoma. Cancer Sci. 104:1455–1460. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ishida K, Ando N, Yamamoto S, Ide H and
Shinoda M: Phase II study of cisplatin and 5-fluorouracil with
concurrent radiotherapy in advanced squamous cell carcinoma of the
esophagus: A Japan Esophageal Oncology Group (JEOG)/Japan Clinical
Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 34:615–619.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stewart DJ, Dulberg CS, Mikhael NZ,
Redmond MD, Montpetit VA and Goel R: Association of cisplatin
nephrotoxicity with patient characteristics and cisplatin
administration methods. Cancer Chemother Pharmacol. 40:293–308.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
National Cancer Institute, . Common
Terminology Criteria for Adverse Events v.3.0 and v.4.0 (CTCAE).
2011, http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
|
|
20
|
Lajer H, Kristensen M, Hansen HH, Nielsen
S, Frøkiaer J, Ostergaard LF, Christensen S, Daugaard G and
Jonassen TE: Magnesium depletion enhances cisplatin-induced
nephrotoxicity. Cancer Chemother Pharmacol. 56:535–542. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
van Angelen AA, Glaudemans B, van der Kemp
AW, Hoenderop JG and Bindels RJ: Cisplatin-induced injury of the
renal distal convoluted tubule is associated with hypomagnesaemia
in mice. Nephrol Dial Transplant. 28:879–889. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Solanki MH, Chatterjee PK, Gupta M, Xue X,
Plagov A, Metz MH, Mintz R, Singhal PC and Metz CN: Magnesium
protects against cisplatin-induced acute kidney injury by
regulating platinum accumulation. Am J Physiol Renal Physiol.
307:F369–F384. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vokes EE, Mick R, Vogelzang NJ, Geiser R
and Douglas F: A randomised study comparing intermittent to
continuous administration of magnesium aspartate hydrochloride in
cisplatin-induced hypomagnesaemia. Br J Cancer. 62:1015–1017. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martin M, Diaz-Rubio E, Casado A, López
Vega JM, Sastre J and Almenarez J: Intravenous and oral magnesium
supplementations in the prophylaxis of cisplatin-induced
hypomagnesemia. Results of a controlled trial. Am J Clin Oncol.
15:348–351. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Willox JC, McAllister EJ, Sangster G and
Kaye SB: Effects of magnesium supplementation in testicular cancer
patients receiving cis-platin: A randomised trial. Br J Cancer.
54:19–23. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carney SL, Ray C, Ebeling PR, Martin TJ
and Gillies AH: Synthetic human parathyroid hormone-related protein
and rat renal electrolyte transport. Miner Electrolyte Metab.
17:41–45. 1991.PubMed/NCBI
|
|
27
|
Jaïs P, Bouizar Z, Binn M, Vissuzaine C,
Hayem G, Mignon M and Lewin MJ: Parathyroid hormone-related protein
in an esophageal squamous cell carcinoma with tumor-induced
hypercalcemia. Am J Gastroenterol. 92:343–346. 1997.PubMed/NCBI
|
|
28
|
Arany I and Safirstein RL: Cisplatin
nephrotoxicity. Semin Nephrol. 23:460–464. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Naafs MA, Hackeng WH, Koorevaar G and
Silberbusch J: Abnormal responsiveness of nephrogenous cyclic AMP
excretion following intravenously administered calcium in
normocalcaemic squamous cell cancer patients. Bone Miner.
4:289–298. 1988.PubMed/NCBI
|
|
30
|
Suh SM, Tashjian AH Jr, Matsuo N,
Parkinson DK and Fraser D: Pathogenesis of hypocalcemia in primary
hypomagnesemia: Normal end-organ responsiveness to parathyroid
hormone, impaired parathyroid gland function. J Clin Invest.
52:153–160. 1973. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yap AS, Mortimer RH, Jacobi JM, Galligan
JP, Perry-Keene DA and Khafagi FA: Blunted parathyroid response to
correction of hypercalcemia in subjects with squamous cell
carcinoma. Horm Res. 40:222–226. 1993. View Article : Google Scholar : PubMed/NCBI
|
